Mobile

A multi-centre, open-label, Proof of Concept (PoC) study to evaluate the efficacy and tolerability of STI571 for the treatment of fibrosis in patients with systemic sclerosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-004669-17

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy of oral STI571 in skin fibrosis in systemic sclerosis (SSc) patients as measured by an improvement in the modified Rodnan Skin Score. To assess the safety and tolerability of oral STI571 in SSc patients.

Critère d'inclusion

  • sistemic sclerosis

Liens